Literature DB >> 10805336

Benzodiazepine receptor binding in Huntington's disease: [11C]flumazenil uptake measured using positron emission tomography.

G Künig1, K L Leenders, R Sanchez-Pernaute, A Antonini, P Vontobel, A Verhagen, I Günther.   

Abstract

We used positron emission tomography and [11C]flumazenil to analyze the benzodiazepine receptor binding in symptomatic and asymptomatic carriers of the Huntington's disease gene. We found an inverse relationship between [11C]flumazenil and [11C]raclopride binding in the putamen of symptomatic patients, and interpret this result as GABA receptor upregulation.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10805336

Source DB:  PubMed          Journal:  Ann Neurol        ISSN： 0364-5134            Impact factor:   10.422


  12 in total

Review 1.  Positron emission tomography imaging in neurological disorders.

Authors:  Marios Politis; Paola Piccini
Journal:  J Neurol       Date:  2012-09       Impact factor: 4.849

2.  The de-ubiquitinating enzyme ataxin-3 does not modulate disease progression in a knock-in mouse model of Huntington disease.

Authors:  Li Zeng; Sara J Tallaksen-Greene; Bo Wang; Roger L Albin; Henry L Paulson
Journal:  J Huntingtons Dis       Date:  2013

Review 3.  Imaging the role of GABA in movement disorders.

Authors:  Henning Boecker
Journal:  Curr Neurol Neurosci Rep       Date:  2013-10       Impact factor: 5.081

Review 4.  Using advances in neuroimaging to detect, understand, and monitor disease progression in Huntington's disease.

Authors:  H D Rosas; A S Feigin; Steven M Hersch
Journal:  NeuroRx       Date:  2004-04

Review 5.  PET/CT in diagnosis of movement disorders.

Authors:  Valentina Berti; Alberto Pupi; Lisa Mosconi
Journal:  Ann N Y Acad Sci       Date:  2011-06       Impact factor: 5.691

6.  Cross sectional PET study of cerebral adenosine A₁ receptors in premanifest and manifest Huntington's disease.

Authors:  Andreas Matusch; Carsten Saft; David Elmenhorst; Peter H Kraus; Ralf Gold; Hans-Peter Hartung; Andreas Bauer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-25       Impact factor: 9.236

Review 7.  Alteration of GABAergic neurotransmission in Huntington's disease.

Authors:  Maurice Garret; Zhuowei Du; Marine Chazalon; Yoon H Cho; Jérôme Baufreton
Journal:  CNS Neurosci Ther       Date:  2018-02-21       Impact factor: 5.243

Review 8.  Functional imaging in Huntington's disease.

Authors:  Jane S Paulsen
Journal:  Exp Neurol       Date:  2009-01-03       Impact factor: 5.330

Review 9.  Current status of PET imaging in Huntington's disease.

Authors:  Gennaro Pagano; Flavia Niccolini; Marios Politis
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-02-22       Impact factor: 9.236

Review 10.  Molecular Imaging Markers to Track Huntington's Disease Pathology.

Authors:  Heather Wilson; Rosa De Micco; Flavia Niccolini; Marios Politis
Journal:  Front Neurol       Date:  2017-01-30       Impact factor: 4.003
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.